Hoth Therapeutics Reports 100% Response Rate in Cancer Trial, Reducing Disease Severity by Half
核心洞察
Hoth Therapeutics' HT-001 achieved 100% clinical response in cancer patients receiving EGFR (搜索) inhibitor therapy, with all evaluable patients reaching low-severity disease status by Week 6.
The CLEER-001 trial demonstrated a 50% reduction in disease severity using the ARIGA scale, alongside 34% improvement in oncology toxicity and 37% reduction in patient-reported pruritus.
Results showed rapid onset of improvement as early as Week 3 with sustained benefits through Week 6, highlighting HT-001's potential as supportive care for cancer patients on EGFR (搜索) inhibitors.
Hoth Therapeutics has reported promising interim results from its CLEER-001 clinical trial, with HT-001 achieving a 100% clinical response rate in cancer patients receiving EGFR (搜索) inhibitor therapy. The open-label pharmacokinetic cohort demonstrated significant improvements across multiple clinical endpoints, positioning the investigational topical therapy as a potential breakthrough in oncology supportive care.
Primary Endpoint Shows Dramatic Disease Severity Reduction
The trial's primary endpoint assessed disease severity using the ARIGA scale, revealing substantial clinical benefits. Mean ARIGA scores improved from 1.67 at baseline to 0.83 at Week 6, representing an approximate 50% reduction in severity. Notably, all evaluable patients reached ARIGA ≤1 by Week 6, placing the entire cohort within the low-severity disease range.
"These results represent a meaningful milestone for HT-001," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "Seeing 100% clinical response in the open-label PK cohort, along with a ~50% reduction in disease severity and additional improvements in oncology toxicity and patient-reported symptoms, underscores the potential of HT-001 to improve the treatment experience for cancer patients receiving EGFR (搜索) inhibitors."
The improvements demonstrated both rapid onset and durability, with benefits observed as early as Week 3 and maintained through Week 6.
Broad Clinical Benefits Across Multiple Measures
Beyond the primary endpoint, HT-001 showed meaningful improvements across additional clinically relevant measures. Investigator-assessed CTCAE scores improved from 2.0 at baseline to 1.33 at Week 6, representing approximately 34% improvement in treatment-related toxicity. CTCAE serves as a core oncology toxicity scale frequently used to guide dose modification, interruption, or discontinuation of cancer therapies.
Patient-reported pruritus scores also showed significant improvement, declining from 4.22 at baseline to 2.67 at Week 6, representing a 37% reduction in symptom severity. This level of improvement exceeds commonly accepted thresholds for clinically meaningful benefit and directly impacts patient comfort, quality of life, and treatment adherence.
Addressing Critical Unmet Need in Cancer Care
EGFR (搜索) inhibitors represent cornerstone therapies across multiple major cancer indications, including lung, colorectal, and head-and-neck cancers. However, treatment-related toxicity and symptom burden remain among the most common and dose-limiting challenges, often impacting treatment continuity and outcomes. The CLEER-001 results highlight HT-001's potential to serve as an important oncology supportive-care therapy, helping patients remain on effective, life-extending cancer treatments.
Safety Profile and Development Path
HT-001 demonstrated favorable tolerability in the open-label PK cohort, with no unexpected safety signals observed. The pharmacokinetic portion of CLEER-001 was designed to evaluate exposure, tolerability, and early clinical signal. The observed consistent improvements across investigator-assessed and patient-reported endpoints support the selected dosing regimen and continued clinical development.
HT-001 is Hoth Therapeutics' proprietary topical therapy under investigation for the management of treatment-related toxicity and symptom burden in cancer patients receiving targeted therapies, including EGFR (搜索) inhibitors. The company continues to advance the CLEER-001 trial as part of its broader clinical development program.